FP-025

Foresee Pharmaceuticals Co., Ltd. · Phase 1 active Small molecule

At a glance

Generic name	FP-025
Sponsor	Foresee Pharmaceuticals Co., Ltd.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

The Effect of FP-025, on Allergen-induced Airway Responses in Mild Eosinophilic House Dust Mite (HDM)-Allergic Asthma. (PHASE2)
A Phase 2/3 Study to Evaluate FP-025 in Patients With Severe to Critical COVID 19 (PHASE2, PHASE3)
Phase 1 Safety, Tolerability and Pharmacokinetics (PK) Study of FP-025 in Healthy Volunteers (PHASE1)
A Phase 1, Pharmacokinetics of the MMP-12 Inhibitor FP-025 After Multiple Oral Ascending Doses in Healthy Subjects (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

FP-025 CI brief — competitive landscape report
FP-025 updates RSS · CI watch RSS
Foresee Pharmaceuticals Co., Ltd. portfolio CI